Q3 2017 · —
Revenue$17.50M$17.50M no prior Q3 2016 on file+13.9% vs Q2 2017
Net Income-$1.42M-$1.42M no prior Q3 2016 on fileN/M vs Q2 2017
EPS Diluted-$3.14-$3.14 no prior Q3 2016 on fileN/M vs Q2 2017
Operating Income-$1,065,000—
Margins · derived
Operating margin-6.1%
Net margin-8.1%
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-Q.
Same quarter
no prior Q3 2016 on file
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Sutro Biopharma, Inc. · CIK 1382101 · Engraved from SEC EDGAR